Key result
High neuropeptide-Y levels post-STEMI are linked to greater microvascular obstruction and reduced 6-month LVEF.
Why the study?
Neuropeptide-Y (NPY) is released during high sympathetic drive such as STEMI and acts as a potent vasoconstrictor. Whether myocardial NPY levels correlate with reperfusion and recovery after primary PCI, and whether and how NPY constricts the coronary microvasculature, required investigation.
Do elevated myocardial neuropeptide-Y levels correlate with microvascular dysfunction and reduced ejection fraction in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention?
Observational (n=109)
Do elevated myocardial neuropeptide-Y levels correlate with microvascular dysfunction and reduced ejection fraction in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention?
High coronary sinus neuropeptide-Y levels immediately after reperfusion in STEMI patients correlate with microvascular dysfunction, greater myocardial injury, and reduced ejection fraction at 6 months, mediated via Y1 receptor-induced microvascular constriction.
Answers are grounded in this paper and cite their sources.
Neuropeptide-Y levels may identify STEMI patients at higher risk of microvascular injury; leaves open whether Y1 antagonism improves recovery.
AIMS: The co-transmitter neuropeptide-Y (NPY) is released during high sympathetic drive, including ST-elevation myocardial infarction (STEMI), and can be a potent vasoconstrictor. We hypothesized that myocardial NPY levels correlate with reperfusion and subsequent recovery following primary percutaneous coronary intervention (PPCI), and sought to determine if and how NPY constricts the coronary microvasculature. METHODS AND RESULTS: Peripheral venous NPY levels were significantly higher in patients with STEMI (n = 45) compared to acute coronary syndromes/stable angina ( n = 48) or with normal coronary arteries (NC, n = 16). Overall coronary sinus (CS) and peripheral venous NPY levels were significantly positively correlated (r = 0.79). STEMI patients with the highest CS NPY levels had significantly lower coronary flow reserve, and higher index of microvascular resistance measured with a coronary flow wire. After 2 days they also had significantly higher levels of myocardial oedema and microvascular obstruction on cardiac magnetic resonance imaging, and significantly lower ejection fractions and ventricular dilatation 6 months later. NPY (100-250 nM) caused significant vasoconstriction of rat microvascular coronary arteries via increasing vascular smooth muscle calcium waves, and also significantly increased coronary vascular resistance and infarct size in Langendorff hearts. These effects were blocked by the Y1 receptor antagonist BIBO3304 (1 μM). Immunohistochemistry of the human coronary microvasculature demonstrated the presence of vascular smooth muscle Y1 receptors. CONCLUSION: High CS NPY levels immediately after reperfusion correlate with microvascular dysfunction, greater myocardial injury, and reduced ejection fraction 6 months after STEMI. NPY constricts the coronary microcirculation via the Y1 receptor, and antagonists may be a useful PPCI adjunct therapy.
No takes yet. Share an insight, caveat, or question.
Herring et al. (2019) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=109). High coronary sinus neuropeptide-Y (NPY) levels vs. Lower coronary sinus NPY levels / ACS or normal coronary arteries was evaluated on Microvascular dysfunction, myocardial injury, and left ventricular ejection fraction at 6 months (r = 0.79 (correlation between coronary sinus and peripheral venous NPY)). High coronary sinus neuropeptide-Y levels correlated with peripheral levels and were associated with greater microvascular obstruction and reduced 6-month ejection fraction post-STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: